The Week in Review: China Offers Lion's Share of Emerging Market Growth

IMS Health said China is “in a league of its own” among the 17 “pharmerging” countries that represent $90 billion of future growth in pharmaceutical markets; Shanghai’s Zhangjiang Hi-Tech Park has signed a cooperation agreement with its counterpart in Sweden, Uppsala BIO; MicuRx Pharmaceuticals filed an IND with the SFDA for a new antibiotic drug candidate; Sinovac Biotech (北京科兴生物制品有限公司) has signed up Parenteral Drugs India to distribute its pandemic flu vaccines in India; Novartis said revenues in China grew 36% last year; China Sky One Medical (中国天字一号医药公司) expects 2010 revenues to grow by 20% to $156 million; Vycor Medical will seek SFDA approval for its medical device used during brain surgery; Lee's Pharma will distribute an antihypertensive drug for Recordati; and the FDA has warned XiAn Libang Pharma it must improve its quality control procedures, if it wants to continue importing products to the US. More details… Stock Symbols: (NYSE: IMS) (NYSE: SVA) (BSE: 524689) (NYSE: NVS) (NSDQ: CSKI) (OTCBB: VYCO) (GEM: 8221) (MI: RECI)